Published in Ann Rheum Dis on June 01, 2005
Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis (2007) 4.88
Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol (2010) 1.23
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 6.36
EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.59
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum (2004) 3.46
A human Y-linked DNA polymorphism and its potential for estimating genetic and evolutionary distance. Science (1985) 2.88
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis (2007) 2.60
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Trading genes along the silk road: mtDNA sequences and the origin of central Asian populations. Am J Hum Genet (1998) 2.32
Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM (2007) 2.14
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) (2006) 1.94
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) (2001) 1.82
Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (1999) 1.79
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis (2010) 1.73
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol (1998) 1.66
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
Systemic sclerosis (scleroderma): an integrated challenge in rehabilitation. Arch Phys Med Rehabil (1997) 1.62
Sex-specific migration patterns in Central Asian populations, revealed by analysis of Y-chromosome short tandem repeats and mtDNA. Am J Hum Genet (1999) 1.61
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
Progress in systemic sclerosis: a 10-year perspective. Rheumatology (Oxford) (2009) 1.44
Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol (1997) 1.43
The measurement of outcome and the rheumatoid arthritis core set to lift the prejudice of the 'thaumaturgus cliche'. Rheumatology (Oxford) (2006) 1.42
Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res (Hoboken) (2012) 1.40
Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis. Arthritis Rheum (2001) 1.39
High free and latent collagenase activity in psoriatic arthritis synovial fluids. Br J Rheumatol (1994) 1.39
Suppression of autoantibodies to factor VIII and correction of factor VIII deficiency with a combined steroid-cyclophosphamide-porcine factor VIII treatment in a patient with rheumatoid arthritis. J Intern Med (1992) 1.38
Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) (2001) 1.35
Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis (2008) 1.32
Hypertrophic osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol (1993) 1.30
Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) (2009) 1.29
Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis (2007) 1.26
Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. Rheumatology (Oxford) (2006) 1.24
The clinical spectrum of pachydermoperiostosis (primary hypertrophic osteoarthropathy). Medicine (Baltimore) (1991) 1.23
Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis (2010) 1.22
Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum (2012) 1.13
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis (2008) 1.13
QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J (2008) 1.13
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) (2008) 1.12
Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum (2001) 1.11
Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum (1999) 1.10
Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum (2003) 1.10
The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis (2009) 1.09
Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother (1998) 1.09
Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur Respir J (2009) 1.08
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann Rheum Dis (2009) 1.08
Mechanisms of vascular damage in SSc--implications for vascular treatment strategies. Rheumatology (Oxford) (2008) 1.07
Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis (2007) 1.07
Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis (2011) 1.05
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis (2006) 1.05
Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis (2010) 1.05
Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology (Oxford) (2008) 1.04
Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum (1995) 1.02
Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) (2001) 1.01
Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM (2009) 1.01
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant (2004) 1.01
Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease. Ann Rheum Dis (2008) 1.00
Characterization of an evolutionarily conserved far-upstream enhancer in the human alpha 2(I) collagen (COL1A2) gene. J Biol Chem (2001) 1.00
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. Ann Rheum Dis (2008) 0.99
Thoracic myelolipoma diagnosed by endoscopic ultrasonography and fine-needle aspiration cytology. Endoscopy (2007) 0.99
Metal stent placement in acute malignant colorectal obstruction. Dig Liver Dis (2006) 0.99
Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum (2007) 0.99
Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. Arthritis Rheum (2011) 0.98
NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet (2000) 0.98
Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol (1998) 0.97
Macrophage activation results in bone resorption. Clin Orthop Relat Res (1998) 0.97
Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) (2005) 0.97
Cutaneous fibrinolytic activity in primary hypertrophic osteoarthropathy. Scand J Rheumatol (1987) 0.97
Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotype. Arthritis Rheum (2011) 0.96
Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford) (2006) 0.96
Carotid and femoral arterial wall mechanics in scleroderma. Rheumatology (Oxford) (2003) 0.96
Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol (2010) 0.96
Cardiac involvement in HIV-related non-Hodgkin's lymphoma: a case report and short review of the literature. Ann Hematol (1998) 0.96
Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis (2008) 0.95
Assessment of lung involvement. Clin Exp Rheumatol (2003) 0.95
Association of a KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. Arthritis Rheum (2010) 0.94
The management of systemic sclerosis. Br J Rheumatol (1995) 0.94
The Italian version of the Mouth Handicap in Systemic Sclerosis scale (MHISS) is valid, reliable and useful in assessing oral health-related quality of life (OHRQoL) in systemic sclerosis (SSc) patients. Rheumatol Int (2011) 0.94
Platelet activation in allergic asthma patients during allergen challenge with Dermatophagoides pteronyssinus. Clin Exp Allergy (2006) 0.94
Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology (2000) 0.94
Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis (2004) 0.94
The psychological impact of facial changes in scleroderma. Psychol Health Med (2011) 0.94
Efficacy of a tailored rehabilitation program for systemic sclerosis. Clin Exp Rheumatol (2009) 0.93
Neurogenic influences in arthritis: potential modification by capsaicin. J Rheumatol (1995) 0.92
Assessment of skin, joint, tendon and muscle involvement. Clin Exp Rheumatol (2003) 0.92
Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. J Rheumatol (1998) 0.92
Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum (1998) 0.92
Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis Rheum (1997) 0.92
Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management. Eur Respir Rev (2010) 0.91
Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut (2005) 0.91